Season 13 · Episode 3
S13 Ep3: Updated Nilotinib Formulation Improves Treatment Adherence in Ph+ CML: With Michael J. Mauro, MD
OncLive® On Air · OncLive® On Air
May 19, 202512m 59s
Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In today’s episode, supported by Azurity Pharmaceuticals, we spoke with Michael J. Mauro, MD, about treatment adherence with nilotinib (Tasigna/Danziten) in patients with Philadelphia chromosome (Ph)–positive chronic myeloid leukemia (CML). Dr Mauro is an attending physician at Memorial Sloan Kettering Cancer Center in New York, New York.
In our exclusive interview, Dr Mauro discussed barriers to nilotinib treatment adherence in patients with Ph-positive CML, ways that nonadherence can diminish quality of life and clinical response to treatment, ways that the new formulation of nilotinib addresses adherence issues by reducing the need for fasting, and ongoing research into alternative formulations of other agents that may further improve CML treatment efficacy and tolerability.
In our exclusive interview, Dr Mauro discussed barriers to nilotinib treatment adherence in patients with Ph-positive CML, ways that nonadherence can diminish quality of life and clinical response to treatment, ways that the new formulation of nilotinib addresses adherence issues by reducing the need for fasting, and ongoing research into alternative formulations of other agents that may further improve CML treatment efficacy and tolerability.